Drug Patent List
Oppositions
Newsletter
Weekly Digest

Pharsight

Selpercatinib Patent Expiration

Selpercatinib is Used for treating advanced or metastatic thyroid cancer and non-small cell lung cancer with specific genetic mutations that are refractory to other treatments. It was first introduced by Loxo Oncology Inc A Wholly Owned Sub Of Eli Lilly And Co in its drug Retevmo on May 8, 2020.


Selpercatinib Patents

Given below is the list of patents protecting Selpercatinib, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Retevmo US10112942 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors Oct 10, 2037 Loxo Oncol Eli Lilly
Retevmo US10112942 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors Oct 10, 2037 Loxo Oncol Eli Lilly
Retevmo US10137124 Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors Oct 10, 2037 Loxo Oncol Eli Lilly
Retevmo US10137124 Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors Oct 10, 2037 Loxo Oncol Eli Lilly
Retevmo US10172851 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors Oct 10, 2037 Loxo Oncol Eli Lilly
Retevmo US10172851 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors Oct 10, 2037 Loxo Oncol Eli Lilly
Retevmo US10584124 Crystalline forms Oct 10, 2038 Loxo Oncol Eli Lilly
Retevmo US10584124 Crystalline forms Oct 10, 2038 Loxo Oncol Eli Lilly
Retevmo US10786489 Formulations of 6-(2-hydroxy-2-methylpropxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-A]pyridine-3-carbonitrile Oct 10, 2038 Loxo Oncol Eli Lilly
Retevmo US10786489 Formulations of 6-(2-hydroxy-2-methylpropxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-A]pyridine-3-carbonitrile Oct 10, 2038 Loxo Oncol Eli Lilly


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Selpercatinib's patents.

Given below is the list recent legal activities going on the following patents of Selpercatinib.

Event Date Patent/Publication
Patent litigations
Payment of Maintenance Fee, 4th Yr, Small Entity 21 Feb, 2024 US10786489
Payment of Maintenance Fee, 4th Year, Large Entity 23 Aug, 2023 US10584124
Payment of Maintenance Fee, 4th Year, Large Entity 22 Jun, 2022 US10172851
Payment of Maintenance Fee, 4th Year, Large Entity 21 Apr, 2022 US10137124
Payment of Maintenance Fee, 4th Year, Large Entity 22 Mar, 2022 US10112942
Post Issue Communication - Certificate of Correction 25 Nov, 2020 US10786489
Sequence Moved to Public Database 29 Sep, 2020 US10786489
Recordation of Patent Grant Mailed 29 Sep, 2020 US10786489
Patent Issue Date Used in PTA Calculation 29 Sep, 2020 US10786489
Email Notification 15 Sep, 2020 US10786489



Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳